NCT07020221 2026-04-22
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Recruiting
Verastem, Inc.
National Cancer Institute (NCI)
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Gruppo Oncologico del Nord-Ovest
Phanes Therapeutics
Taiho Pharmaceutical Co., Ltd.